一个"绿色"的工具箱:用于控制反动物的胃肠道线虫的非化疗方法
Miguel Peña-Espinoza1, Hannah Rose Vineer2, Adam D Hayward3
1Institute of Parasitology, Centre of Pathobiology, Department of Biological Sciences and Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria.
Trends in parasitology
|August 12, 2025
概括
由于寄生虫的耐药性,减少牧草反动物对虫药物的依赖是至关重要的. 本研究回顾了胃肠道线虫控制的绿色,非化疗干预措施,突出了进展和未来的方向.
科学领域:
- 兽医寄生虫学 兽医寄生虫学
- 动物科学动物科学
- 可持续农业 可持续农业
背景情况:
- 放牧的反动物面临着严重的健康和生产损失来自胃肠道线虫.
- 增加抗虫药物耐药性需要使用替代的寄生虫控制策略.
- 越来越需要有效的非化疗干预措施,特别是在绿色/有机农业系统中.
研究的目的:
- 提供一种非化疗工具的最新概述,用于控制反动物的胃肠道线虫.
- 突出最近的科学进展,并确定"绿色"寄生虫管理策略的知识差距.
- 探索新型研究和技术如何促进这些干预措施的开发和实施.
主要方法:
- 关于控制反动物线虫的非化疗干预措施的最新科学文献的综述.
- 分析目前的发展状况,并提供各种"绿色"控制策略的证据.
- 识别与寄生虫控制相关的新兴研究方法和技术.
主要成果:
- 选择的非化疗工具显示出对胃肠道线虫控制的前景.
- 对于许多"绿色"战略,存在重大知识差距和碎片化的证据.
- 新的研究和技术正在出现,用于测试和实施.
结论:
- 整合非化疗干预措施需要解决当前的知识差距和不同发展水平.
- 研究和技术的进步是开发和实施可持续的寄生虫控制的关键.
- 对宿主-寄生虫-环境相互作用的全面理解对于有效的"绿色"反动物生产至关重要.
相关概念视频
Biological Methods for Microbial Control
202
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
202
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
401
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
401
Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Peptic Ulcer Disease IV: Management
146
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
146


